WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
View the documentIntroduction
Open this folder and view contentsParasitic infections
Open this folder and view contentsInsect and arachnid bites and stings
Open this folder and view contentsSuperficial fungal infections
Open this folder and view contentsSubcutaneous fungal infections
Open this folder and view contentsBacterial infections
Open this folder and view contentsViral infections
Open this folder and view contentsEczematous diseases
Open this folder and view contentsScaling diseases
Open this folder and view contentsPapulosquamous diseases
View the documentCutaneous reactions to drugs
Open this folder and view contentsPigmentary disorders
Open this folder and view contentsPremalignant lesions and malignant tumours
Open this folder and view contentsPhotodermatoses
Open this folder and view contentsBullous dermatoses
View the documentAlopecia areata
View the documentUrticaria
Open this folder and view contentsConditions common in children
View the documentAcne vulgaris
View the documentPruritus
View the documentTropical ulcers
Open this folder and view contentsAntimicrobial drugs
Open this folder and view contentsAntifugal drugs
Open this folder and view contentsAntiseptic agents
Open this folder and view contentsKeratoplastic and keratolytic agents
Open this folder and view contentsScabicides and pediculicides
Open this folder and view contentsAnti-inflammatory and antipruritic drugs1
Open this folder and view contentsAntiallergics and drugs used in anaphylaxis
Close this folderUltraviolet radiation-blocking agents (sunscreens)
View the documentp-Aminobenzoic acid (PABA)
View the documentBenzophenones, cinnamates, dibenzoylmethanes, salicylates
View the documentTitanium dioxide
View the documentZinc oxide
Open this folder and view contentsMiscellaneous drugs
Open this folder and view contentsAnnex
View the documentSelected WHO Publications of Related Interest
View the documentBack cover
 

Titanium dioxide

SPF 15 or above, broad-spectrum
Cream or ointment

General information

Titanium dioxide is an inert compound that is used in powders, creams or ointments as a protectant against solar radiation. In the microfine form, which is being used with increasing frequency, it is a white powder and is placed in suspension in concentrations varying from 1% to 10%. This form may be used in association with ultraviolet radiation-absorbing agents. In the standard form it may be used at concentrations of up to 25%.

Clinical information

Uses

To prevent sunburn, premature ageing of the skin, and skin cancer and related lesions. It may also provide protection from photosensitive disorders caused by sunlight in both the ultraviolet A and ultraviolet B range.

Dosage and administration

Adults and children: products containing titanium dioxide in the microfine form should be applied to all exposed areas of skin at least 30 minutes before exposure to sunlight. Creams or ointments containing high concentrations of the standard form are suitable for use on small areas of sensitive skin such as the nose, cheeks and ears.

Precautions

The microfine form may have a slightly opalescent appearance in suspension which may make it cosmetically unacceptable for some people. The standard form is unsuitable for use on large areas of skin because of its colour, smell and texture.

Storage

Preparations should be stored below 30 °C.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019